AEON Biopharma, Inc IPO Research Information

AEON Biopharma, Inc IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on AEON Biopharma, Inc, and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
AEON Biopharma, Inc	AEON - NASDAQ	Postponed	$0.00	$0.00	Postponed	10/8/2021
Underwriter(s): Wells Fargo, Cantor, Mizuho Securities
Co-Manager(s): HC Wainwright & Co.
Industry: Health Care
Filing(s): Filed 2021-09-17 Terms Added 2021-10-04

About AEON Biopharma, Inc (adapted from AEON Biopharma, Inc prospectus):
They are a clinical stage biopharmaceutical company focused on developing our proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, or ABP-450, for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "AEON" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.